Cargando…

Verification of a Western Nomogram for Predicting Oncotype DX™ Recurrence Scores in Korean Patients with Breast Cancer

A recent study conducted at the University of Tennessee Medical Center using a large dataset from the National Cancer Database (NCDB) reported the use of nomograms for predicting Oncotype DX™ (ODX) scores with clinicopathologic data. We reviewed the data of 218 patients who underwent the ODX test at...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Jae-Myung, Ryu, Jai Min, Kim, Isaac, Choi, Hee Jun, Nam, Seok Jin, Kim, Seok Won, Yu, Jonghan, Lee, Se Kyung, Lee, Jeong Eon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Breast Cancer Society 2018
Materias:	Brief Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6015974/ https://www.ncbi.nlm.nih.gov/pubmed/29963119 http://dx.doi.org/10.4048/jbc.2018.21.2.222

Ejemplares similares

A Novel Surrogate Nomogram Capable of Predicting OncotypeDX Recurrence Score©
por: Davey, Matthew G., et al.
Publicado: (2022)

Oncotype DX Recurrence Score in premenopausal women
por: Zhang, Shiliang, et al.
Publicado: (2022)

The analytical validation of the Oncotype DX Recurrence Score assay
por: Baehner, Frederick L
Publicado: (2016)

Nomogram for accurate prediction of breast and axillary pathologic response after neoadjuvant chemotherapy in node positive patients with breast cancer
por: Choi, Hee Jun, et al.
Publicado: (2019)

Impact of Oncotype DX Recurrence Score on the Patterns of Locoregional Recurrence in Breast Cancer (Korean Radiation Oncology Group 19-06)
por: Kim, Kyubo, et al.
Publicado: (2020)

Low utility of Oncotype DX® in the clinic
por: Ricks‐Santi, Luisel J., et al.
Publicado: (2017)

Oncotype DX breast cancer recurrence score can be predicted with a novel nomogram using clinicopathologic data
por: Orucevic, Amila, et al.
Publicado: (2017)

MiRNA expression deregulation correlates with the Oncotype DX(®) DCIS score
por: Loudig, Olivier, et al.
Publicado: (2022)

Examination of the Biomark assay as an alternative to Oncotype DX for defining chemotherapy benefit
por: Kim, Jinkyoung, et al.
Publicado: (2019)

Oncotype DX: Where Does It Stand in India?
por: Batra, Atul, et al.
Publicado: (2019)

Clinicopathological Factors Associated with Oncotype DX Risk Group in Patients with ER+/HER2- Breast Cancer
por: Song, Ran, et al.
Publicado: (2023)

Ki 67 is a major, but not the sole determinant of Oncotype Dx recurrence score
por: Sahebjam, S, et al.
Publicado: (2011)

Correlation of Oncotype DX Recurrence Score with Histomorphology and Immunohistochemistry in over 500 Patients
por: Hanna, Matthew G., et al.
Publicado: (2017)

Improving Therapeutic Ratios with the Oncotype DX® Ductal Carcinoma In Situ (DCIS) Score
por: Lalani, Nafisha, et al.
Publicado: (2017)

Fertility Rates in Young Korean Breast Cancer Patients Treated with Gonadotropin-Releasing Hormone and Chemotherapy
por: Kim, Isaac, et al.
Publicado: (2017)

Treatment Choices Based on OncotypeDx in the Breast Oncology Care Setting
por: Malo, Teri L., et al.
Publicado: (2012)

Association Between Phosphorylated Histone H3 and Oncotype DX Recurrence Scores in Breast Cancer
por: Lee, Lik Hang, et al.
Publicado: (2017)

Oncotype Dx Results in Multiple Primary Breast Cancers
por: Toole, Michael J., et al.
Publicado: (2014)

Spotlight on the utility of the Oncotype DX(®) breast cancer assay
por: Siow, Zhen Rong, et al.
Publicado: (2018)

Erratum: Development of a Nomogram to Predict N2 or N3 Stage in T1-2 Invasive Breast Cancer Patients with No Palpable Lymphadenopathy
por: Kim, Isaac, et al.
Publicado: (2018)

Serum Trace Elements and Their Associations with Breast Cancer Subgroups in Korean Breast Cancer Patients
por: Choi, Rihwa, et al.
Publicado: (2018)

Oncotype DX recurrence score implications for disparities in chemotherapy and breast cancer mortality in Georgia
por: Collin, Lindsay J., et al.
Publicado: (2019)

A Nomogram for Predicting the Oncotype DX Recurrence Score in Women with T1-3N0-1miM0 Hormone Receptor‒Positive, Human Epidermal Growth Factor 2 (HER2)‒Negative Breast Cancer
por: Lee, Sae Byul, et al.
Publicado: (2019)

Validation of Korean Version of the COmprehensive Score for Financial Toxicity (COST) among Breast Cancer Survivors
por: Shim, Sungkeun, et al.
Publicado: (2022)

Development of a Nomogram to Predict N2 or N3 Stage in T1–2 Invasive Breast Cancer Patients with No Palpable Lymphadenopathy
por: Kim, Isaac, et al.
Publicado: (2017)

Survival results according to Oncotype Dx recurrence score in patients with hormone receptor positive HER-2 negative early-stage breast cancer: first multicenter Oncotype Dx recurrence score survival data of Turkey
por: Ünal, Çağlar, et al.
Publicado: (2023)

Patterns of Axillary Lymph Node Metastasis in Breast Cancer: A Prospective Single-Center Study
por: Choi, Hee Jun, et al.
Publicado: (2018)

Use of Oncotype DX in Women with Node-Positive Breast Cancer
por: Ishibe, Naoko, et al.
Publicado: (2011)

Utilization of Oncotype DX in an Inner City Population: Race or Place?
por: Guth, Amber A., et al.
Publicado: (2013)

Radiomics signature on 3T dynamic contrast-enhanced magnetic resonance imaging for estrogen receptor-positive invasive breast cancers: Preliminary results for correlation with Oncotype DX recurrence scores
por: Nam, Kyung Jin, et al.
Publicado: (2019)

BCL-2 expression aids in the immunohistochemical prediction of the Oncotype DX breast cancer recurrence score
por: Zarella, Mark D., et al.
Publicado: (2018)

Development and validation for research assessment of Oncotype DX® Breast Recurrence Score, EndoPredict® and Prosigna®
por: Buus, Richard, et al.
Publicado: (2021)

MRI Radiomics and Machine Learning for the Prediction of Oncotype Dx Recurrence Score in Invasive Breast Cancer
por: Romeo, Valeria, et al.
Publicado: (2023)

Comparison of GenesWell BCT Score With Oncotype DX Recurrence Score for Risk Classification in Asian Women With Hormone Receptor-Positive, HER2-Negative Early Breast Cancer
por: Kwon, Mi Jeong, et al.
Publicado: (2019)

Validation of the Clinical Treatment Score Post–Five Years in Breast Cancer Patients for Predicting Late Distant Recurrence: A Single-Center Investigation in Korea
por: Lee, Jun-Hee, et al.
Publicado: (2021)

Prediction of the Oncotype DX recurrence score: use of pathology-generated equations derived by linear regression analysis
por: Klein, Molly E, et al.
Publicado: (2013)

Impact of Oncotype DX Recurrence Score on Treatment Decisions: Results of a Prospective Multicenter Study in Turkey
por: Ozmen, Vahit, et al.
Publicado: (2016)

Comparison of Core Needle Biopsy and Surgical Specimens in Determining Intrinsic Biological Subtypes of Breast Cancer with Immunohistochemistry
por: You, Kiho, et al.
Publicado: (2017)

Clinicopathological Characterization of Double Heterozygosity for BRCA1 and BRCA2 Variants in Korean Breast Cancer Patients
por: Bang, Yoon Ju, et al.
Publicado: (2022)

Prognostic Validation of the American Joint Committee on Cancer 8th Staging System in 24,014 Korean Patients with Breast Cancer
por: Kim, Isaac, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_cs0ch2damh9mgpo37tsuvgcqeo